ArticleFrontline gastroenterology2021
Anti-
Article in Frontline gastroenterology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it, 21 citations in OpenAlex.
- Multistage pathogenesis and disease associations ofFrontiers in immunology · 2026Pooled it
- Advances in paratuberculosis research and control: a comprehensive expert review.BMC veterinary research · 2026Review
- Influence of landscape on the distribution of inflammatory bowel disease in England and Wales.BMC public health · 2026Article
- Nervous Breakdown: Chronic Inflammatory Demyelinating Polyneuropathy as an Extra-Intestinal Manifestation of Ulcerative Colitis.Digestive diseases and sciences · 2025Article
- Cutaneous and Genitalia Inflammation Treated With Guselkumab and Antimicrobial Therapy in a Patient with a History of Crohn's Disease.ACG case reports journal · 2025Article
- Viewpoint: The Use of Antimycobacterial (Anti-MAP) Therapies in the Treatment of Active Luminal Crohn's Disease.JGH open : an open access journal of gastroenterology and hepatology · 2025Review
- Discovery ofAntibiotics (Basel, Switzerland) · 2024Article
- Randomized, Double-Blind, Placebo-Controlled Study of Anti-Mycobacterial Therapy (RHB-104) in Active Crohn's Disease.Antibiotics (Basel, Switzerland) · 2024Article
- Mapping Crohn's Disease Pathogenesis with Mycobacterium paratuberculosis: A Hijacking by a Stealth Pathogen.Digestive diseases and sciences · 2024Review
- Perioperative Considerations for the Surgical Treatment of Crohn's Disease with Discussion on Surgical Antibiotics Practices and Impact on the Gut Microbiome.Antibiotics (Basel, Switzerland) · 2024Review
- Antibiotic Therapy for Active Crohn's Disease Targeting Pathogens: An Overview and Update.Antibiotics (Basel, Switzerland) · 2024Review
- The evidence forTranslational cancer research · 2023Review
- Review
- The dual role of interleukin-6 in Crohn's disease pathophysiology.Frontiers in immunology · 2023Review
- Quantitative Risk Assessment of Exposure toFoods (Basel, Switzerland) · 2022Article
- Putting Crohn's on the MAP: Five Common Questions on the Contribution of Mycobacterium avium subspecies paratuberculosis to the Pathophysiology of Crohn's Disease.Digestive diseases and sciences · 2021Review
- Anti-MAP Triple Therapy Supports Immunomodulatory Therapeutic Response in Crohn's Disease through Downregulation of NF-κB Activation in the Absence of MAP Detection.Biomedicines · 2020Article
- Rifabutin-Loaded Nanostructured Lipid Carriers as a Tool in Oral Anti-Mycobacterial Treatment of Crohn's Disease.Nanomaterials (Basel, Switzerland) · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The role of
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.